Flu infection study increases understanding of natural immunity

People with higher levels of antibodies against the stem portion of the influenza virus hemagglutinin (HA) protein have less viral shedding when they get the flu, but do not have fewer or less severe signs of illness, according to a new study.

3D print of hemagglutinin (HA), one of the proteins found on the surface of influenza virus. Image credit: NIAID

HA sits on the surface of the influenza virus to help bind it to cells and features a head and stem region. Scientists only recently discovered that humans naturally generate anti-HA stem antibodies in response to flu infection, and this is the first study of its kind to evaluate pre-existing levels of these specific antibodies as a predictor of protection against influenza.

The findings could have implications for flu vaccine development, according to the authors. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, conducted the research.

The study team has explored immune responses to two influenza surface proteins: HA—the main target of traditional seasonal flu vaccines—and neuraminidase (NA).

The head region of HA is constantly changing, which is why influenza vaccine strains must be updated each year. The HA stem region, however, is less susceptible to change, making it a potential target for novel vaccines aimed at broader, more durable protection.

In the new analysis, investigators sought to understand the role of pre-existing anti-HA stem antibodies in protection against influenza.

They found that all volunteers had anti-HA stem antibodies at baseline, although levels varied, and 64 percent of participants had increased levels after infection. However, people with higher levels before exposure had smaller increases, suggesting there could be a limit that humans can achieve naturally.

Trial investigators also closely monitored participants’ symptoms and the amount of influenza virus they shed from the nose, which may indicate how contagious someone is.

Similar to findings regarding anti-HA head antibodies, they found that participants with higher baseline levels of anti-HA stem antibodies had reduced viral shedding, but no significant reduction in the duration or severity of illness.

The results show that people naturally make anti-HA stem antibodies, but that responses vary significantly, and also these antibody levels are not independent predictors of whether someone becomes sick or if so, how severely.

The authors note that antibodies against NA remain the only identified predictor of disease severity, according to previously reported trial data. (National Institutes of Health)

YOU MAY ALSO LIKE

Probiotics May Not Always Be A Silver Bullet for Better Health

To combat the effects of a poor diet, probiotics may be just the thing. However, surprising new research from UNSW suggests probiotics are much less effective when taken alongside a balanced diet, and could even impair certain aspects of memory.

Hormone treatment studied in older men

Hormone treatment for one year may improve bone strength and reduce anemia for some older men with a low level of testosterone. But it might also increase cardiovascular risk.

Long-term consumption of sunflower and fish oils damages the liver

An international group of scientists led by the University of Granada has demonstrated that the long-term intake of sunflower or fish oils damages the liver and can cause a series of alterations in it, giving rise to non-alcoholic steatohepatitis.

Baby teeth link autism and heavy metals

Baby teeth from children with autism contain more toxic lead and less of the essential nutrients zinc and manganese, compared to teeth from children without autism.

New Approach to Predict Respiratory Allergy in Early Childhood

A new study suggests that immune response in early childhood to a handful of allergen molecules can predict the onset of allergic rhinitis and asthma in adolescence.

Cellular immunotherapy targets a common human cancer mutation

In a study of an immune therapy for colorectal cancer that involved a single patient, a team of researchers at the National Cancer Institute identified a method for targeting the cancer-causing protein produced by a mutant form of the KRAS gene.